, pub-4214183376442067, DIRECT, f08c47fec0942fa0
19.1 C
New York
Sunday, May 28, 2023

FDA approves 1st RSV vaccine

The U.S. Meals and Drug Administration (FDA) has authorized the world’s first-ever vaccine to forestall respiratory syncytial virus (RSV) — a seasonal respiratory an infection that may trigger life-threatening pneumonia and harmful irritation of the lungs in high-risk teams — the company introduced (opens in new tab) Wednesday (Could 3).

The authorized vaccine, known as Arexvy and made by the pharmaceutical firm GlaxoSmithKline (GSK), has been cleared to be used in a type of high-risk teams: adults ages 60 and older. Infants and younger youngsters make up the opposite high-risk group, and vaccines for them are nonetheless being developed. One shot, designed to be given in being pregnant so protecting antibodies can cross via the placenta to the fetus, is nearing approval. 

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles